Search

Displaying results 7171 - 7180 of 10000 in total
  1. Drug

    Talbutal

    go.drugbank.com/drugs/DB00306
    ApprovedIllicit

    Talbutal is a schedule III drug in the U.S.

  2. Drug

    LIC-477

    go.drugbank.com/drugs/DB05363
    Experimental

    LIC-477is indicated to be suitable for the treatment of psychosomatic disturbances, epilepsy, trigeminal neuralgia and cerebral spasticity.

  3. Drug

    Depatuxizumab mafodotin

    go.drugbank.com/drugs/DB11731
    Investigational

    Depatuxizumab/Denintuzumab mafodotin has been used in trials studying the treatment of Lymphoma, Gliosarcoma, Glioblastoma, Malignant Glioma, Squamous Cell Tumors, and Glioblastoma Multiforme.

  4. Drug

    Perhexiline

    go.drugbank.com/drugs/DB01074
    Approved

    Perhexiline is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.

  5. Drug

    EpiVacCorona

    go.drugbank.com/drugs/DB16439
    Investigational

    EpiVacCorona Vaccine, developed by the Vektor State Research Center of Virology and Biotechnology in Russia, is based on peptide-antigens that facilitate immunity to the SARS-CoV-2 virus[L30608]. … It is currently being tested in Phase I/II clinical trials for safety and immunogenicity (NCT04527575)[L30608, L30613].

    Categories: Complex Mixtures
  6. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational

  7. Drug

    TBC-3711

    go.drugbank.com/drugs/DB05407
    Investigational

    TBC3711 is a next-generation endothelin antagonist that is being studied through oral and intravenous formulations by Encysive Pharmaceuticals.

  8. Drug

    PA-1050040

    go.drugbank.com/drugs/DB06039
    Experimental

    PA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.

  9. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor. It is developed for the treatment of obesity and other metabolic disorders.

  10. Drug

    AVR118

    go.drugbank.com/drugs/DB04979
    Investigational

    AVR118 is being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs (including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment … for its ability to stimulate the immune system to attack tumor cells (especially those cancer cells that have been damaged by chemotherapeutic agents) and for its ability to treat cachexia (wasting) in